The Use of Antifungal Therapy in Neonatal Intensive Care

Overview

Journal Clin Perinatol

Date 2012 Feb 21

PMID 22341539

Citations 6

Authors

Daniela Testoni

P Brian Smith

Daniel K Benjamin Jr

Affiliations

Soon will be listed here.

Abstract

Invasive fungal infections remain a significant cause of infection-related mortality and morbidity in preterm infants. Central nervous system involvement is the hallmark of neonatal candidiasis, differentiating the disease's impact on young infants from that among all other patient populations. Over the past decade, the number of antifungal agents in development has grown, but most are not labeled for use in newborns. We summarize the findings of several antifungal studies that have been completed to date, emphasizing those including infant populations. We conclude that more studies are required for antifungals to be used safely and effectively in infants.

Citing Articles

Ototoxic and nephrotoxic drugs in neonatal intensive care units: results of a Spanish and Italian survey.

Arribas C, Decembrino N, Raffaeli G, Amodeo I, Gonzalez-Caballero J, Riaza M Eur J Pediatr. 2024; 183(6):2625-2636.

PMID: 38492032 DOI: 10.1007/s00431-024-05467-w.

Diagnosis and Treatment of Invasive Candidiasis.

Barantsevich N, Barantsevich E Antibiotics (Basel). 2022; 11(6).

PMID: 35740125 PMC: 9219674. DOI: 10.3390/antibiotics11060718.

Invasive fungal infections in neonates: a review.

Weimer K, Smith P, Puia-Dumitrescu M, Aleem S Pediatr Res. 2021; 91(2):404-412.

PMID: 34880444 DOI: 10.1038/s41390-021-01842-7.

High-Dose Micafungin in Neonates and Young Infants with Invasive Candidiasis: Results of a Phase 2 Study.

Auriti C, Goffredo B, Ronchetti M, Piersigilli F, Cairoli S, Bersani I Antimicrob Agents Chemother. 2021; 65(4).

PMID: 33558294 PMC: 8097467. DOI: 10.1128/AAC.02494-20.

Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Roberts J, Stockmann C, Constance J, Stiers J, Spigarelli M, Ward R Clin Pharmacokinet. 2014; 53(7):581-610.

PMID: 24871768 DOI: 10.1007/s40262-014-0147-0.

References

Galgiani J . Fluconazole, a new antifungal agent. Ann Intern Med. 1990; 113(3):177-9. DOI: 10.7326/0003-4819-113-3-177. View

Leitner J, Meyer B, Fuhrmann V, Saria K, Zuba C, Jager W . Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2011; 66(4):880-4. DOI: 10.1093/jac/dkq545. View

Sun Q, Fothergill A, McCarthy D, Rinaldi M, Graybill J . In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002; 46(5):1581-2. PMC: 127128. DOI: 10.1128/AAC.46.5.1581-1582.2002. View

Cowen E, Nguyen J, Miller D, McShane D, Arron S, Prose N . Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2009; 62(1):31-37. PMC: 2815347. DOI: 10.1016/j.jaad.2009.09.033. View

Le J, Adler-Shohet F, Nguyen C, Lieberman J . Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009; 28(12):1061-3. DOI: 10.1097/INF.0b013e3181af6201. View

Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T . Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008; 27(9):820-6. DOI: 10.1097/INF.0b013e31817275e6. View

Shima H, Miharu M, Osumi T, Takahashi T, Shimada H . Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010; 54(7):1050-2. DOI: 10.1002/pbc.22451. View

Weitkamp J, Ozdas A, LaFleur B, Potts A . Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol. 2008; 28(6):405-11. DOI: 10.1038/sj.jp.7211914. View

Neely M, Jafri H, Seibel N, Knapp K, Adamson P, Bradshaw S . Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2008; 53(4):1450-6. PMC: 2663098. DOI: 10.1128/AAC.01027-08. View

10.

Zaoutis T, Jafri H, Huang L, Locatelli F, Barzilai A, Ebell W . A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009; 123(3):877-84. DOI: 10.1542/peds.2008-1158. View

11.

Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely O . Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008; 28(10):1223-32. DOI: 10.1592/phco.28.10.1223. View

12.

Makhoul I, Kassis I, Smolkin T, Tamir A, Sujov P . Review of 49 neonates with acquired fungal sepsis: further characterization. Pediatrics. 2001; 107(1):61-6. DOI: 10.1542/peds.107.1.61. View

13.

Mistry G, Migoya E, Deutsch P, Winchell G, Hesney M, Li S . Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007; 47(8):951-61. DOI: 10.1177/0091270007303764. View

14.

Pfaller M, Diekema D, Boyken L, Messer S, Tendolkar S, Hollis R . Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother. 2005; 49(11):4795-7. PMC: 1280139. DOI: 10.1128/AAC.49.11.4795-4797.2005. View

15.

Soltani M, Tobin C, Bowker K, Sunderland J, MacGowan A, Lovering A . Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 2006; 28(6):574-7. DOI: 10.1016/j.ijantimicag.2006.07.013. View

16.

Benjamin Jr D, Smith P, Arrieta A, Castro L, Sanchez P, Kaufman D . Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2009; 87(1):93-9. PMC: 2824925. DOI: 10.1038/clpt.2009.200. View

17.

Wildfeuer A, Laufen H, Schmalreck A, Yeates R, Zimmermann T . Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses. 1998; 40(7-8):259-65. DOI: 10.1111/j.1439-0507.1997.tb00230.x. View

18.

Doby E, Benjamin Jr D, Blaschke A, Ward R, Pavia A, Martin P . Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J. 2012; 31(6):632-5. PMC: 3356483. DOI: 10.1097/INF.0b013e31824acc33. View

19.

Natarajan G, Lulic-Botica M, Aranda J . Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol. 2009; 29(11):738-43. DOI: 10.1038/jp.2009.75. View

20.

Sheehan D, Hitchcock C, Sibley C . Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999; 12(1):40-79. PMC: 88906. DOI: 10.1128/CMR.12.1.40. View